Financials
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
ASND Catalyst Timeline
Dated clinical, regulatory and corporate events for Ascendis Pharma A/S
Catalyst Timeline
Dated clinical, regulatory & corporate events for Ascendis Pharma A/S
Upcoming catalysts 2
Event history 50
Past FDA Catalysts and PDUFA Decisions
How ASND actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-10-09 | TransCon PTH (palopegteriparatide) | Phase 2 data presentation | Phase 2 |
Drug Pipeline Intelligence
| Product | Revenue | Prior period | Change |
|---|---|---|---|
| YORVIPATH® | |||
| SKYTROFA® |
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Lonapegsomatropin BiologicsNCT05690386 | Turner Syndrome | Phase 3 | ACTIVE NOT_RECRUITING | 234 | Dec 1, 2027 | ||||||
| Palopegteriparatide PeptidesMarketedNCT07081997 | Hypoparathyroidism | Approved | RECRUITING | 48 | Jun 1, 2028 | ||||||
| Navepegritide PeptidesMarketedNCT06732895 | Achondroplasia | Approved | ACTIVE NOT_RECRUITING | 203 | Oct 1, 2027 | ||||||
| Navepegritide PeptidesNCT07917143 | Hypochondroplasia | Phase 3 | NOT YET_RECRUITING | 81 | Oct 1, 2029 | ||||||
| Dual therapy with navepegritide and lonapegsomatropin Small MoleculesMarketedNCT07924059 | Achondroplasia | Approved | NOT YET_RECRUITING | 144 | Sep 1, 2029 | ||||||
| Lonapegsomatropin Small MoleculesMarketedNCT04615273 | Growth Hormone Deficiency | Approved | COMPLETED | 264 | Dec 1, 2023 | ||||||
| Lonapegsomatropin Small MoleculesMarketedNCT05171855 | Adult Growth Hormone Deficiency | Approved | COMPLETED | 220 | Dec 23, 2024 | ||||||
| TransCon PTH Small MoleculesMarketedNCT04009291 | Hypoparathyroidism | Approved | COMPLETED | 143 | Apr 17, 2025 | ||||||
| TransCon hGH BiologicsMarketedNCT03344458 | Growth Hormone Deficiency | Approved | COMPLETED | 444 | Feb 21, 2023 | ||||||
| TransCon CNP Small MoleculesMarketedNCT05246033 | Achondroplasia | Approved | COMPLETED | 221 | Apr 23, 2024 | ||||||
| ACP-001 Small MoleculesMarketedNCT01247675 | Adult Growth Hormone Deficiency | Approved | COMPLETED | 37 | May 1, 2011 | ||||||
| ACP-001 Small MoleculesMarketedNCT01947907 | Growth Hormone Deficiency (GHD) | Approved | COMPLETED | 53 | Sep 1, 2015 |
Clinical Trial Results
Readouts, endpoints and source filings for every ASND program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| TransCon PTH Priority | hypoparathyroidism | Phase 2/3 | 2026-10-26 | 68.9% of patients achieving clinically meaningful increases in eGFR; mean improvement in eGFR for all patients from baseline to Week 26 was 7.2 mL/min/1.73 m2; mean improvement in eGFR to Week 52 was 9.6 mL/min/1.73 m2; 49.6% of patients achieved an increase in eGFR of >10 mL/min /1.73 m2; mean eGFR slope was 0.28 mL/min/1.73 m2/year; 24-hour urine calcium excretion normalized from mean 396 mg/day at baseline to mean 206 mg/day at Week 26; mean serum calcium increased to 8.9 mg/dL; 98% of patients achieved independence from active vitamin D; 95% of patients achieved independence from therapeutic doses of calciumRead More | TransCon® PTH (Palopegteriparatide) Demonstrates Sustained, Clinically Meaningful Improvements in Kidney Function in Adults with Hypoparathyroidism Treated Up to 5 YearsRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Bodenhoff MadsOfficer (SVP & PAO) | Option | 3,000 3,000 held | $110.00 | 09/08/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in ASND
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. | 23.5 % (-1.3 %) | 2.34 B | 10.28 M |
Ownership Trends
ASND Short Interest
Shares sold short, counted twice a month.
Options Data
Option Volume
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-20 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
Competitive positioning
How ASND ranks across every disease it competes in
ASND News
Ascendis Pharma Reports Third Quarter 2026 Financial Results
Ascendis Pharma reported a strong Q3 2026, with product revenue reaching €366 million, up 89% year-over-year. The company received positive opinions for TransCon CNP from the CHMP and COMP, with a final EC decision expected in Q4 2026. The first EU launch is planned for Germany in Q1 2027, with pivotal data anticipated in Q3 2027.
Read more →Ascendis Pharma to Participate in the Jefferies London Healthcare Conference
Ascendis Pharma A/S will participate in the Jefferies London Healthcare Conference on November 17, 2026. Executives will engage in a fireside chat, and a live webcast will be accessible on the company's website. This event highlights Ascendis' commitment to innovative therapies using their TransCon technology platform.
Read more →Once-Weekly TransCon® CNP (Navepegritide) to Receive 10 Years of Market Exclusivity Upon Approval in the European Union
Ascendis Pharma announced a positive recommendation from the EMA's COMP for its once-weekly TransCon CNP for treating achondroplasia in children. This designation could grant 10 years of market exclusivity upon final approval by the European Commission, expected in Q4 2026. The company anticipates launching the treatment in Germany in Q1 2027.
Read more →Ascendis to Report Third Quarter 2026 Financial Results and Provide Business Update on November 12, 2026
Ascendis Pharma A/S announced plans to report its third quarter 2026 financial results on November 12, 2026. The company will also provide a business update and host a conference call at 8:00 a.m. ET. The event will be accessible via a live webcast, with a replay available for 30 days.
Read more →TransCon® PTH (Palopegteriparatide) Demonstrates Sustained, Clinically Meaningful Improvements in Kidney Function in Adults with Hypoparathyroidism Treated Up to 5 Years
Ascendis Pharma announced positive results from its Phase 2 and Phase 3 trials of TransCon PTH for hypoparathyroidism. The treatment showed significant improvements in kidney function, with 68.9% of patients achieving clinically meaningful increases in eGFR. Additionally, most patients reported independence from conventional therapies and maintained normal serum calcium levels.
Read more →Once-Weekly TransCon® CNP (Navepegritide) Receives Positive CHMP Opinion for the Treatment of Achondroplasia in Children
Ascendis Pharma announced that the CHMP has issued a positive opinion for marketing authorization of TransCon CNP (navepegritide) for treating achondroplasia in children aged two and older. The final decision by the European Commission is anticipated in Q4 2026, with a potential launch in Germany in Q1 2027. TransCon CNP is designed to provide continuous exposure to active CNP, addressing overactive FGFR3 signaling.
Read more →Ascendis to Share Latest Advances in Hypoparathyroidism and Achondroplasia Programs at ASBMR 2026
Ascendis Pharma will present updates on its hypoparathyroidism and achondroplasia programs at ASBMR 2026. Key highlights include findings from the Phase 2 and Phase 3 trials demonstrating improvements in bone mass and microarchitecture in patients treated with TransCon PTH. The company emphasizes the potential of its therapies to enhance patient outcomes and quality of life.
Read more →Ascendis Announces Planned $400 Million Share Repurchase Program
Ascendis Pharma A/S has announced a $400 million share repurchase program authorized by its Board of Directors. The program allows for repurchases through various methods, depending on market conditions. This initiative reflects the company's confidence in its financial standing and aims to enhance shareholder value.
Read more →Ascendis to Regain Rights to TransCon® Technology in Metabolic and Cardiovascular Diseases
Ascendis Pharma has announced it will regain exclusive rights to develop TransCon technology-based products in metabolic and cardiovascular diseases, including obesity. This follows the termination of its collaboration with Novo Nordisk. Ascendis plans to initiate multiple new programs, including advancing once-monthly TransCon Semaglutide as a treatment for obesity and type 2 diabetes.
Read more →First Infant Data from Ascendis Trial of Once-Weekly TransCon CNP (Navepegritide) Presented at ESPE 2026
Ascendis Pharma presented positive Week 52 data from the reACHin Trial for TransCon CNP, showing stabilization or improvement in foramen magnum stenosis and enhanced linear growth in infants with achondroplasia. The treatment was well tolerated, with no significant adverse events reported. The results suggest that early intervention with TransCon CNP could effectively address growth limitations and medical complications associated with the condition.
Read more →Ascendis Pharma to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference
Ascendis Pharma A/S will participate in the Morgan Stanley 24th Annual Global Healthcare Conference on September 15, 2026. Executives will engage in a fireside chat, which will be available via live webcast and for replay on their website. The company emphasizes its focus on innovative therapies using its TransCon technology platform.
Read more →Ascendis to Share Its Latest Endocrinology Rare Disease Data at ESPE 2026
Ascendis Pharma will present new data from its Endocrinology Rare Disease programs at ESPE 2026 in Marseille. Key highlights include the first cohort data from the pivotal reACHin Trial of TransCon CNP in infants with achondroplasia. The company aims to demonstrate the potential benefits of early intervention in this patient population.
Read more →Ascendis and BioMarin Enter Binding Term Sheet for a Global Settlement and License Agreement Related to YUVIWEL® (Navepegritide)
Ascendis Pharma has entered a binding term sheet with BioMarin for a global settlement and license agreement concerning YUVIWEL and related products. The agreement resolves all litigation and allows Ascendis to develop and commercialize navepegritide-related products. Ascendis anticipates substantial revenue growth and aims to achieve €5 billion in revenue by 2030.
Read more →Ascendis Announces Oral Presentation of Week 104 Data from Its Pivotal Trial of TransCon® CNP (Navepegritide) at ISDS 2026
Ascendis Pharma announced an oral presentation of Week 104 data from its pivotal ApproaCH Trial at ISDS 2026. The trial focuses on TransCon CNP (navepegritide) for treating achondroplasia in children. The data indicates significant benefits, including improvements in height and physical functioning, with a favorable safety profile. The FDA has already approved TransCon CNP under the name YUVIWEL.
Read more →Ascendis Pharma Reports Second Quarter 2026 Financial Results
Ascendis Pharma reported a significant increase in product revenue for Q2 2026, totaling €315 million, driven by strong sales of YORVIPATH, SKYTROFA, and YUVIWEL. The company highlighted successful trial data presentations and completion of key enrollment milestones. Ascendis also settled its convertible notes and was added to multiple Russell U.S. Indexes, indicating a strong market position.
Read more →Ascendis to Report Second Quarter 2026 Financial Results and Provide Business Update on August 13, 2026
Ascendis Pharma A/S announced plans to report its second quarter 2026 financial results and provide a business update on August 13, 2026. A conference call will follow the report, allowing investors to engage with the company. The announcement highlights Ascendis' commitment to transparency and innovation in addressing patient needs.
Read more →Ascendis Announces COACH Week 78 Results and Provides Update on Achondroplasia Programs and YUVIWEL® Uptake in the U.S.
Ascendis Pharma announced positive results from the Phase 2 COACH Trial, showing significant growth improvements in children with achondroplasia using TransCon CNP and TransCon hGH combination therapy. The company also reported successful enrollment in the pivotal reACHin Trial for infants and noted a strong uptake of YUVIWEL in the U.S., with over 65% of patients approved for reimbursement.
Read more →Children with Achondroplasia Treated with TransCon CNP Showed Continued Improvements in Lower Extremity Alignment at Week 104 of the Pivotal ApproaCH Trial
Ascendis Pharma reported positive results from the ApproaCH Trial, showing that children with achondroplasia treated with TransCon CNP demonstrated sustained improvements in lower extremity alignment over 104 weeks. The trial highlighted significant reductions in tibial-femoral angle, particularly in children with preexisting genu varum. The treatment was well tolerated, with no serious adverse events reported.
Read more →Ascendis Joins Multiple Russell U.S. Indexes, Including the Russell 3000®, Russell 1000®, Russell 2500® and Russell Midcap®
Ascendis Pharma A/S has announced its inclusion in several Russell U.S. Indexes, including the Russell 3000, Russell 1000, Russell 2500, and Russell Midcap. This change is effective as of June 26, 2026, and reflects the company's growing market presence. The Russell Indexes are widely utilized by investment managers, indicating potential for increased investment interest.
Read more →Ascendis to Showcase Advances in Treatment of Achondroplasia at ICCBH 2026
Ascendis Pharma will present new data on treatments for achondroplasia at ICCBH 2026. The presentations include Week 104 data from the pivotal ApproaCH Trial and findings from the COACH Trial. These results highlight the benefits of TransCon CNP and its combination with TransCon hGH, addressing significant unmet needs in affected children.
Read more →